PMID- 17106885
OWN - NLM
STAT- MEDLINE
DCOM- 20070227
LR  - 20220409
IS  - 0736-0266 (Print)
IS  - 0736-0266 (Linking)
VI  - 25
IP  - 2
DP  - 2007 Feb
TI  - Platelet rich plasma (PRP) enhances anabolic gene expression patterns in flexor 
      digitorum superficialis tendons.
PG  - 230-40
AB  - Platelet rich plasma (PRP) has recently been investigated for use in tissue 
      regeneration studies that seek to utilize the numerous growth factors released 
      from platelet alpha-granules. This study examined gene expression patterns, DNA, 
      and collagen content of equine flexor digitorum superficialis tendon (SDFT) 
      explants cultured in media consisting of PRP and other blood products. Blood and 
      bone marrow aspirate (BMA) were collected from horses and processed to obtain 
      plasma, PRP, and platelet poor plasma (PPP). IGF-I, TGF-beta1, and PDGF-BB were 
      quantified in all blood products using ELISA. Tendons were cultured in explant 
      fashion with blood, plasma, PRP, PPP, or BMA at concentrations of 100%, 50%, or 
      10% in serum-free DMEM with amino acids. Quantitative RT-PCR for expression of 
      collagen type I (COL1A1), collagen type III (COL3A1), cartilage oligomeric matrix 
      protein (COMP), decorin, matrix metalloproteinase-3 (MMP-3), and matrix 
      metalloproteinase-13 (MMP-13) was performed as were DNA and total soluble 
      collagen assays. TGF-beta1 and PDGF-BB concentrations were higher in PRP compared 
      to all other blood products tested. Tendons cultured in 100% PRP showed enhanced 
      gene expression of the matrix molecules COL1A1, COL3A1, and COMP with no 
      concomitant increase in the catabolic molecules MMP-3 and MMP-13. These findings 
      support in vivo investigation of PRP as an autogenous, patient-side treatment for 
      tendonitis.
FAU - Schnabel, Lauren V
AU  - Schnabel LV
AD  - Department of Clinical Sciences, VMC C3-181, Cornell University, Ithaca, New York 
      14853, USA.
FAU - Mohammed, Hussni O
AU  - Mohammed HO
FAU - Miller, Brian J
AU  - Miller BJ
FAU - McDermott, William G
AU  - McDermott WG
FAU - Jacobson, May S
AU  - Jacobson MS
FAU - Santangelo, Kelly S
AU  - Santangelo KS
FAU - Fortier, Lisa A
AU  - Fortier LA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Orthop Res
JT  - Journal of orthopaedic research : official publication of the Orthopaedic 
      Research Society
JID - 8404726
RN  - 0 (Extracellular Matrix Proteins)
RN  - 0 (Glycoproteins)
RN  - 0 (Matrilin Proteins)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (Proto-Oncogene Proteins c-sis)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 1B56C968OA (Becaplermin)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - 9007-34-5 (Collagen)
RN  - 9007-49-2 (DNA)
SB  - IM
MH  - Animals
MH  - Becaplermin
MH  - Collagen/genetics/metabolism
MH  - DNA/genetics/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Extracellular Matrix Proteins/genetics/metabolism
MH  - Gene Expression Regulation/*physiology
MH  - Glycoproteins/genetics/metabolism
MH  - Horses
MH  - Insulin-Like Growth Factor I/genetics/metabolism
MH  - Matrilin Proteins
MH  - Metabolism/genetics/*physiology
MH  - Platelet-Derived Growth Factor/genetics/metabolism
MH  - *Platelet-Rich Plasma/physiology
MH  - Proto-Oncogene Proteins c-sis
MH  - RNA, Messenger/genetics/metabolism
MH  - Tendinopathy/drug therapy
MH  - Tendons/*metabolism
MH  - Tissue Culture Techniques
MH  - Transforming Growth Factor beta1/genetics/metabolism
EDAT- 2006/11/16 09:00
MHDA- 2007/02/28 09:00
CRDT- 2006/11/16 09:00
PHST- 2006/11/16 09:00 [pubmed]
PHST- 2007/02/28 09:00 [medline]
PHST- 2006/11/16 09:00 [entrez]
AID - 10.1002/jor.20278 [doi]
PST - ppublish
SO  - J Orthop Res. 2007 Feb;25(2):230-40. doi: 10.1002/jor.20278.